Month: August 2024
August 13, 2024
Insignis Therapeutics Receives FDA Fast Track Designation for IN-001 for Anaphylaxis Treatment
- Convenient, needle-free, and simple-to-use liquid epinephrine sublingual spray
- Suitable for all patients, including those with dry mouth conditions, as it does not require saliva for dissolution or absorption
- Unprecedented stability under extreme temperature conditions from -20℃/-4°F to 60℃/140°F, making it the first rugged real-world epinephrine product that can endure extreme heat and cold
- Considerably Longer shelf life than competition products, reducing the need for frequent replacements and ensuring product integrity and performance